Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine

International Clinical Psychopharmacology

Volumn 28, Issue 1, 2013, Pages 20-28

  Goodwin, Guy M ^a   Boyer, Patrice ^b,f   Emsley, Robin ^c   Rouillon, Frédéric ^d   De Bodinat, Christian ^e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OTTAWA   (Canada)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d Sainte Anne Hospital   (France)

^e INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

agomelatine; antidepressant; depression; innovations; relapse

Indexed keywords

AGOMELATINE; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC ACCURACY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SENSITIVITY ANALYSIS; SURVIVAL;

ACETAMIDES; ADULT; ANTIDEPRESSIVE AGENTS; AUSTRALIA; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; RECURRENCE; SEVERITY OF ILLNESS INDEX; SOUTH AFRICA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84871619438     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32835b0814     Document Type: Article

References (30)

1. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG (1975). Quantitative rating of depressive states. Acta Psychiatr Scand 51:161-170.
2. Blom MB, Spinhoven P, Hoffman T, Jonker K, Hoencamp E, Haffmans PM, van Dyck R (2007). Severity and duration of depression, not personality factors, predict short term outcome in the treatment of major depression. J Affect Disord 104:119-126. (Pubitemid 350052321)
3. Fava M, Evins AE, Dorer DJ, Schoenfeld DA (2003). The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 72:115-127. (Pubitemid 36469860)
4. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J (2010). Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 303:47-53.
5. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361:653-661. (Pubitemid 36246547)
6. Goodwin GM, Emsley R, Rembry S, Rouillon F (2009). Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebocontrolled trial. J Clin Psychiatry 70:1128-1137.
7. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication ADM 76-338. Rockville, MD: National Institute of Mental Health; pp. 217-222.
8. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
9. Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, et al. (2010). Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 71:109-120.
10. Kennedy SH, Emsley R (2006). Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 16: 93-100. (Pubitemid 43145814)
11. Khan A, Schwartz K (2005). Study designs and outcomes in antidepressant clinical trials. Essent Psychopharmacol 6:221-226.
12. Khan A, Leventhal RM, Khan SR, Brown WA (2002). Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 22:40-45. (Pubitemid 34101291)
13. Kilts CD, Wade AG, Andersen HF, Schlaepfer TE (2009). Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opin Pharmacother 10:927-936.
14. Kobak KA, Kane JM, Thase ME, Nierenberg AA (2007). Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol 27:1-5. (Pubitemid 46105756)
15. Kornstein SG, Bose A, Li D, Saikali KG, Gandhi C (2006). Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. J Clin Psychiatry 67:1767-1775. (Pubitemid 44955159)
16. Lecrubier Y, Bech P (2007). The Ham D(6) is more homogenous and as sensitive as the Ham D(17). Eur Psychiatry 22:252-255. (Pubitemid 46729750)
17. Leon AC, Shear MK, Portera L, Klerman GL (1992). Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 27:78-82.
18. McGrath PJ, Stewart JW, Quitkin FM, Chen Y, Alpert JE, Nierenberg AA, et al. (2006). Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry 163:1542-1548. (Pubitemid 44465753)
19. Montgomery SA, Kasper S (2007). Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 22:283-291. (Pubitemid 47237547)
20. Nierenberg AA, Quitkin FM, Kremer C, Keller MB, Thase ME (2004). Placebocontrolled continuation treatment with mirtazapine: acute pattern of response predicts relapse. Neuropsychopharmacology 29:1012-1018. (Pubitemid 38526801)
21. Olié JP, Kasper S (2007). Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10:661-673. (Pubitemid 47517525)
22. Perahia DG, Gilaberte I, Wang F, Wiltse CG, Huckins SA, Clemens JW, et al. (2006). Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br J Psychiatry 188:346-353.
23. Rapaport MH, Bose A, Zheng H (2004). Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 65:44-49.
24. Reimherr FW, Amsterdam JD, Quitkin FM, Rosenbaum JF, Fava M, Zajecka J, et al. (1998). Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry 155:1247-1253. (Pubitemid 28402520)
25. Santen G, Gomeni R, Danhof M, Della PO (2008). Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy. J Psychiatr Res 42:1000-1009.
26. Sheehan DV, Harnett-Sheehan K, Raj BA (1996). The measurement of disability. Int Clin Psychopharmacol 11 (Suppl 3):89-95. (Pubitemid 26373761)
27. Simon JS, Aguiar LM, Kunz NR, Lei D (2004). Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res 38:249-257. (Pubitemid 38299162)
28. Walsh BT, Seidman SN, Sysko R, Gould M (2002). Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287: 1840-1847. (Pubitemid 34303629)
29. Zigmond AS, Snaith RP (1983). The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361-370. (Pubitemid 13098606)
30. Zimmerman M, Martinez JA, Friedman M, Boerescu DA, Attiullah N, Toba C (2012). How can we use depression severity to guide treatment selection when measures of depression categorize patients differently? J Clin Psychiatry [Epub ahead of print Sept 4].